Physician profile
Elliott Salamon
NPI 1609063486
$48,413.67
in general payments reported to CMS, 2019-2025
57 companies · $5,633 in 2025
The $5,633 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,352 · 2020: $12K · 2021: $7,797 · 2022: $8,893 · 2023: $5,324 · 2024: $4,874 · 2025: $5,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,766 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,050 · Education: $14.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,766.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,050.00 |
| Education | $14.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20,320.07 | 2021-2025 | Linq II, Micra |
| Medtronic Vascular, INC. | $10,803.25 | 2019-2020 | |
| Abbvie INC. | $4,520.62 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Boston Scientific Corporation | $2,668.19 | 2019-2025 | Watchman Flx |
| Sk Life Science, INC. | $1,009.25 | 2020-2025 | |
| Amgen INC. | $806.41 | 2019-2025 | Uplizna |
| Pfizer INC. | $686.99 | 2023-2025 | |
| Grifols USA, LLC | $589.70 | 2019-2025 | Gamunex-C |
| Ucb, INC. | $589.50 | 2019-2024 | Rystiggo |
| Allergan, INC. | $573.96 | 2020-2022 | |
| Eisai INC. | $539.69 | 2019-2025 | |
| Lundbeck LLC | $388.11 | 2020-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $323.32 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $317.01 | 2021-2025 | Hyqvia, Gammagard Liquid |
| Genzyme Corporation | $287.77 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliott Salamon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.